Τόμος 19 (2001) – Τεύχος 3 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 19 (2001) – Issue 3 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Ε. Κουϊμτζόγλου, Α. Χατζάκη, Α. Γραβάνης

Εργαστήριο Φαρμακολογίας, Τμήμα Ιατρικής, Πανεπιστήμιο Κρήτης, Ηράκλειο 71110

E. Kouimtzoglou, A. Chatzaki, A. Gravanis

University of Crete, Faculty of Medicine, Depart­ment of Basic Sciences, Laboratory of Pharma­cology, Heraklion, Crete 71110 Greece

2. Vale W., Vaughan J., Perrin M.: Corticotropin-Releasing Factor (CRF) family of ligands and their receptors. Endocri­nologist 7: 3S-9S (1997)

3. Owens M.J., Nemeroff C.B.: Physiology and pharmacology of corticotropin-releasing factor. Am. Soc. Pharmacol. Exp. Ther. 43: 425-473 (1991)

4. Behan D., DeSouza E., Lowry P., Potter E., Sawchenko P., Vale W.: Corticotropin releasing factor (CRF) binding protein: A novel regulator of CRF and related peptides. Front Neuroendocrinol. 16: 362-382 (1995)

5. Christos T.E., Arvanitis A.: Corticotropin-releasing factor receptor antagonists. Exp. Opin. Ther. Patents 8: 143-152 (1998)

6. McCarthy J.R., Heinrichs S.C., Grigoriadis D.E.: Recent advances with the CRH-R1 receptor: Design of small mole­cule Inhibitors, receptor subtypes and clinical indications. Cur. Pharm. Des. 5: 289-315 (1999)

7. Keller P., Lynette Elfick, Garner J., Morgan J., McCluskey A.: Corticotropin releasing hormone: Therapeu­tic implications and medicinal chemistry developments. Biorg. Med. Chem. 8: 1213-1223 (2000)

8. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B.: The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160: 1-12 (19990

9. Holsboer F.: The rational for CRH receptor antagonists to treat depression and anxiety. J. Psychiatr. Res. 33: 181-214 (1999)

10. Arborelius L., Skelton K.H., Thrivikraman K.V., Plotsky P.M., Schulz D.W., Owens M.J.: Chronic administration of the selective corticotropin-releasing factor 1 receptor an­tagonist CP-154,526: behavioral, endocrine and neuro­chemical effects in the rat. J. Pharmacol. Exp. Ther. 294: 588-597 (2000)

11. Habib K., Weld K., Rice K., Pushkas J., Champoux M., Listwak S., Webster E., Atkinson A., Schulkin J., Chrousos G., McCann S., Suomi S., Higley J., Gold P.: Oral admini­stration of a CRH receptor antagonist significantly attenu­ates behavioural, neuroendocrine and autonomic re­sponses to stress in primates. Proc. Natl. Acad. Sci. USA 23: 97-108 (2000)

12. Zobel A., Nickel T., Kuznel T., Ackl N., Sonntag A., Ising M., Holsboer F.: Effects of the high affinity CRH re­ceptor I antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34: 171-181 (2000)

13. Basso A.M., Spina M., Rivier J., Vale W., Koob G.F.: Corticotropin-releasing factor antagonist attenuates the “anxiogenic-like” effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology 145: 21-30 (1999)

14. Karalis K., Sano H., Redwine J., Listwak S., Wilder R.L., Chrousos G.P.: Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254: 421-423 (1991)

15. Karalis K., Muglia L.J., Bae D., Hilderbrand H., Majzoub J.A.: CRH and the immune system. J. Neuroimmunol. 72: 131-136 (1997)

16. Theoharides T.C., Spanos C., Pang X., Alferes L., Ligris K., Letourneau R., Rozniecki J.J., Webster E., Chrousos G.P.: Stress-induced intracranial mast cell de­granulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 136: 5745-5750 (1995)

17. Theoharides T.C., Singh L.K., Boucher W., Pang X., Letourneau R., Webster E., Chrousos G.: Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 139: 403-413 (1998)

18. Makrigiannakis A., Zoumakis E., Margioris A., Theo­doropoulos P., Stournaras C., Gravanis A.: The Corticotro­pin-Releasing Hormone in normal and tumoral epithelial cells of human endometrium. J. Clin. Endocrinol. Metab. 80: 185-189 (1995)

19. Makrigiannakis A., Margioris A., Zoumakis E., Stourna­ras C., Gravanis A.: The transcription of corticotropin-re­leasing hormone in human endometrial cells is regulated by cytokines. Neuroendocrinology 70: 451-459 (1999)

20. Zoumakis E., Margioris A., Stournaras C., Dermitzaki I., Angelakis E., Makrigiannakis A., Koumantakis E., Gravanis A.: Corticotropin-releasing hormone (CRH) interacts with inflammatory prostaglandins and interleukins and affects decidualization of human endometrial stroma. Mol. Human Reprod. 6: 101-108 (2000)

21. Makrigiannakis A., Margioris A., Chatzaki Α., Zoumakis E., Chrousos G., Gravanis A.: The decidualizing effect of progesterone may involve direct transcriptional activation of corticotropin-releasing hormone (CRH) from human endo­metrial stroma cells. Mol. Human Reprod. 5: 788-796 (1999)

22. Athanassakis I., Farmakiotis V., Aifantis I., Gravanis A., Vassiliadis S.: Expression of corticotrophin-releasing hor­mone in the mouse uterus: participation in embryo implan­tation. J. Endocrinol. 163: 221-227 (1999)

23. Gravanis A., Stournaras C., Margioris A.: Paracrinology of endometrial Neuropeptides: Corticotropin-Releasing Hormone and Opioids. Sem. Reprod. Endocrinol. 17: 29-38 (1999)

24. Chan E.C., Falconer J., Madsen G., Rice K.C., Webster E.L., Chrousos G.P., Smith R.: A corticotropin-releasing hormone type I receptor antagonist delays parturition in sheep. Endocrinology 139: 3357-3360 (1998)

25. Leung T.N., Chung T.K., Madsen G., McLean M., Chang A.M., Smith R.: Elevated mid-trimester maternal corticotrophin-releasing hormone levels in pregnancies that delivered before 34 weeks. Br. J. Obstet. Gynaecol. 106: 1041-1046 (1999)

26. Wong M.L., Webster E.L., Spokes H., Phu P., Ehrhart-Bornstein M., Bornstein S., Park C.S., Rice K.C., Chrousos G.P., Licinio J., Gold P.W.: Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis re­sponses to acute immobilization stress Life Sci. 65: 53-58 (1999)

27. Bornstein S.R., Webster E.L., Torpy D.J., Richman S.J., Mitsiades N., Igel M., Lewis D.B., Rice K.C., Joost H.G., Tsokos M., Chrousos G.P.: Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology 139: 1546-155 (1998)

28. Willenberg H.S., Bornstein S.R., Hiroi N., Path G., Goretzki P.E., Scherbaum W.A., Chrousos G.P.: Effects of a novel corticotropin-releasing hormone receptor type I antagonist on human adrenal function. Mol. Psychiatry 5: 137-141 (2000)